Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis

Toxicology in Vitro

Volumn 25, Issue 7, 2011, Pages 1414-1424

  Tilmant, K ^a,b   Gerets, H H J ^a   Dhalluin, S ^a   Hanon, E ^a   Depelchin, O ^a   Cossu Leguille, C ^b   Vasseur, P ^b   Atienzar, F A ^a  

^a UCB PHARMA   (Belgium)

^b CNRS   (France)

Author keywords

Cellular imaging; Early toxicology; Gene expression; In vivo; Phospholipidosis

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CELL VACUOLE; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LIPIDOSIS; LUNG ALVEOLUS MACROPHAGE; MALE; MOLECULAR IMAGING; NONHUMAN; PREDICTION; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TOXICITY TESTING; VALIDATION PROCESS;

AMIODARONE; ANIMAL TESTING ALTERNATIVES; ANIMALS; ANTI-ARRHYTHMIA AGENTS; FLUORESCENT DYES; FOAM CELLS; GENE EXPRESSION REGULATION; GENOMICS; HEP G2 CELLS; HUMANS; LIPIDOSES; LUNG DISEASES; MACROPHAGES, ALVEOLAR; PHOSPHOLIPIDS; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOXICITY TESTS;

RATTUS;

EID: 84860390397     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.04.010     Document Type: Article

References (40)

1. Atienzar F., Gerets H., Dufrane S., Tilmant K., Cornet M., Dhalluin S., Ruty B., Rose G., Canning M. Determination of phospholipidosis potential based on gene expression analysis in HepG2 Cells. Toxicol. Sci. 2007, 96:101-114.
2. Berridge B.R., Chatman L.A., Odin M., Schultze A.E., Losco P.E., Meehan J.T., Peters T., Vonderfecht S.L. Letter to the editor. Toxicol. Pathol. 2007, 35:325.
3. Bhandari N., Figueroa D.J., Lawrence J.W., Gerhold D.L. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev. Technol. 2008, 6:407-419.
4. Bledsoe G., Shen B., Yao Y., Hagiwara M., Mizell B., Teuton M., Grass D., Chao L., Chao J. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol. Sci. 2008, 102:433-443.
5. Casartelli A., Bonato M., Cristofori P., Crivellente F., Dal Negro G., Masotto I., Mutinelli C., Valko K., Bonfante V. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol. 2003, 19:161-176.
6. Chatman L.A., Morton D., Johnson T.O., Anway S.D. A strategy for risk management of drug-induced phospholipidosis. Toxicol. Pathol. 2009, 37:997-1005.
7. Drenckhahn D., Kleine L., Lüllman-Rauch R. Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab. Invest. 1976, 35:116-123.
8. Fielden M.R., Kolaja K.L. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin. Drug Saf. 2008, 7:107-110.
9. Gonzalez-Rothi R.J., Zander D.S., Ros P.R. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995, 107:1763-1765.
10. Greene N., Naven R. Early toxicity screening strategies. Curr. Opin. Drug Discov. Dev. 2009, 12:90-97.
11. Guiliano K.A., Gough A.H., Taylor D.L., Vernetti L.A., Johnston P.A. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J. Biomol. Screening 2010, 15:783-797.
12. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25:53-60.
13. Hirode M., Ono A., Miyagishima T., Nagao T., Ohno Y., Urushidani T. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol. 2008, 229:290-299.
14. Hutchinson T.H., Mahshid Y., Jönsson R., Björklund C., Kenne K. Proteomic analysis of phospholipidosis in citalopram treated U937 cells - Support for the cholesterol biosynthesis hypothesis. Toxicol. In Vitro 2008, 22:1198-1204.
15. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 2006, 90:133-141.
16. Kodavanti U.P., Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 1990, 42:327-354.
17. Kola I. The state of innovation in drug development. Clin. Pharmacol. Ther. 2008, 83:227-230.
18. Laurent G., Kishore B.K., Tulkens P.M. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem. Pharmacol. 1990, 40:2383-2392.
19. Lorge E., Hayashi M., Albertini S., Kirkland D. Comparison of different methods for an accurate assessment of cytotoxicity in the in vitro micronucleus test. I. Theoretical aspects. Mutat. Res. 2008, 655:1-3.
20. Lüllmann H., Lüllmann-Rauch R. Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses. Toxicol. Appl. Pharmacol. 1981, 61:138-146.
21. Lüllmann H., Lüllmann-Rauch R., Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 1978, 27:1103-1108.
22. Lüllmann-Rauch R., Scheid D. Intraalveolar foam cells associated with lipidosis-like alterations in lung and liver of rats treated with tricyclic psychotropic drugs. Virchows Arch. B Cell. Pathol. 1975, 19:255-268.
23. Miyamoto S., Matsumoto A., Mori I., Horinouchi A. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in the rats. Toxicol. Mech. Methods 2009, 19:477-485.
24. Mesens N., Steemans M., Hansen E., Peters A., Verheyen G., Vanparys P. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Toxicol. In Vitro 2009, 23:217-226.
25. Mesens N., Steemans M., Hansen E., Verheyen G.R., Van Goethem F., Van Gompel J. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol. In Vitro 2010, 24:1417-1425.
26. Monteith D.K., Morgan R.E., Halstead B. In vitro assays and biomarkers for drug-induced phospholipidosis. Expert Opin. Drug Metab. Toxicol. 2006, 2:687-696.
27. Morelli J.K., Buehrle M., Pognan F., Barone L.R., Fieles W., Ciaccio P.J. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. 2006, 22:15-27.
28. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid-based methodologies. Toxicol. Sci. 2007, 99:162-173.
29. Nioi P., Pardo I.D.R., Snyder R.D. Monitoring the accumulation of fluorescently labeled phospholipids in cell cultures provides an accurate screen for drugs that induce phospholipidosis. Drug Chem. Toxicol. 2008, 31:515-528.
30. Obert L.A., Sobocinski G.P., Bobrowski W.F., Metz A.L., Rolsma M.D., Altrogge D.M., Dunstan R.W. An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats. Toxicol. Pathol. 2007, 35:728-734.
31. Pelletier D.J., Gehlhaar D., Tilloy-Ellul A., Johnson T.O., Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model. 2007, 47:1196-1205.
32. Reasor M.J. A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharm. 1989, 97:47-56.
33. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5:567-583.
34. Reasor M.J., Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Exp. Biol. Med. (Maywood) 2001, 226:825-830.
35. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005, 83:282-292.
36. Sawada H., Taniguchi K., Takami K. Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression arrayplate assay. Toxicol. In Vitro 2006, 20:1506-1513.
37. Schneider P., Korolenko T.A., Busch U. A review of drug induced lysosomal disorders of the liver in man and laboratory animals. Microsc. Res. Tech. 1997, 36:253-275.
38. Tomizawa K., Sugano K., Yamada H., Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 2006, 31:315-324.
39. Yamamoto A., Adachi S., Ishikawa K., Yokomura T., Kitani T., Nasu T., Imoto T., Nishikawa M. Studies on drug-induced lipidosis. J. Biochem. 1971, 70:775-784.
40. Whitehouse L.W., Menzies A., Mueller R., Pontefract R. Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology 1994, 94:81-95.